Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp SPIROMAX and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment

Next Previous
Trial Profile

Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp SPIROMAX and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries

Most Recent Events

  • 03 Nov 2016 Status changed from active, no longer recruiting to completed.
  • 13 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2016.
  • 02 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top